TVTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Travere Therapeutics Inc (TVTX) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the technical indicators show some bullish signals, the recent price decline, insider selling, and mixed financial performance suggest caution. Additionally, the lack of strong proprietary trading signals and significant catalysts in the immediate term make this stock a hold rather than a buy.
The MACD is positive and expanding, indicating bullish momentum. The RSI is neutral at 65.925, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock closed below a key resistance level (R1: 30.891) and is showing a pre-market decline of -1.97%, suggesting potential short-term weakness.
Analysts have maintained buy ratings with price targets ranging from $38 to $48, indicating potential upside.
Citi expects FDA approval for Filspari by April 13, which could act as a significant catalyst.
Revenue growth of 73.41% YoY in Q4 2025 shows strong top-line performance.
Insider selling has increased by 667.58% over the last month, which could indicate a lack of confidence from management.
Net income and EPS have declined significantly (-104.53% and -104.17% YoY, respectively), raising concerns about profitability.
The stock has declined by -3.12% in regular trading and -1.97% in pre-market, showing short-term bearish sentiment.
In Q4 2025, revenue increased by 73.41% YoY to $129.69M, and gross margin improved to 98.03%. However, net income dropped by -104.53% YoY to $2.73M, and EPS fell by -104.17% YoY to $0.03, indicating profitability challenges.
Analysts are generally positive on TVTX, with JPMorgan, Citi, and BofA maintaining buy or overweight ratings and price targets between $38 and $48. Citi highlighted an upcoming FDA approval as a potential catalyst, while Piper Sandler remains neutral despite raising its price target to $38.
